Skip to main content
. 2015 Dec 8;6:260. doi: 10.3389/fneur.2015.00260

Table 1.

Cardiovascular baselines prior to 3,4-DAP, i.e., after pre-treatment, and the response to pre-treatment below in parenthesis.

Pre-treatment WKY
SHR
MBP (mm Hg) HR (bpm) TPR (mm Hg/ml/min) MBP (mm Hg) HR (bpm) TPR (mm Hg/ml/min)
PBS Vehicle 65 ± 5
(1 ± 1)
301 ± 15
(−7 ± 5)
2.10.1
(−0.1 ± 0.0)
84 ± 6*
(−5 ± 4)
381 ± 12*
(−8 ± 9)
5.2 ± 0.6*
(−0.7 ± 0.2)
Hemicholinium-3 Ach synthesis inhibitor 58 ± 4
(−26 ± 4)
303 ± 16
(−5 ± 8)
2.1 ± 0.1
(−0.5 ± 0.1)
60 ± 7
(−21 ± 7)
354 ± 14
(−43 ± 9)
3.1 ± 0.2
(−0.9 ± 0.3)
Hexamethonium nAchR antagonist 39 ± 5
(−29 ± 6)
257 ± 12
(−53 ± 14)
1.7 ± 0.1
(−0.7 ± 0.2)
53 ± 2
(−33 ± 7)
345 ± 19
(−67 ± 8)
2.9 ± 0.2
(−1.5 ± 0.2)
Atropine mAchR antagonist 68 ± 10
(−2 ± 3)
307 ± 15
(19 ± 12)
1.7 ± 0.2
(−0.3 ± 0.1)
76 ± 4
(5 ± 7)
374 ± 13
(−33 ± 6)
3.9 ± 0.3
(−0.1 ± 0.2)
Reserpinea + PBS Depletes norepinephrine 58 ± 3
(0 ± 0)
307 ± 4
(−14 ± 4)
2.0 ± 0.1
(0.0 ± 0.0)
62 ± 4
(1 ± 2)
309 ± 12
(−23 ± 5)
4.1 ± 0.3
(0.4 ± 0.1)
Reserpine + atropine 66 ± 4
(−7 ± 2)
328 ± 9
(5 ± 12)
1.9 ± 0.1
(−0.3 ± 0.1)
73 ± 6
(1 ± 2)
278 ± 8
(−19 ± 11)
4.3 ± 0.4
(−0.4 ± 0.3)
Nadolol β1+2AR antagonist 61 ± 4
(2 ± 1)
312 ± 6
(−10 ± 2)
2.0 ± 0.2
(0.0 ± 0.1)
69 ± 5
(−8 ± 3)
343 ± 6
(−67 ± 25)
3.9 ± 0.3
(−0.1 ± 0.2)
Atropine + nadolol Not done 61 ± 9
(−9 ± 4)
325 ± 12
(−33 ± 6)
3.8 ± 0.2
(−0.0 ± 0.2)
Quinidine Antiarrhythmic + KV/KAch inhibitor Not done 67 ± 5
(−42 ± 9)
313 ± 14
(−63 ± 13)
2.5 ± 0.4
(−1.2 ± 0.4)

aSince reserpine was administered prior to the experiment, the effect of reserpine is indicated by the differences in baselines. Comparisons were made between the WKY and SHR controls (*) and between the PBS control and experimental groups within each strain (). Sixteen rats were included in the WKY and SHR controls, and 6–9 rats in the experimental groups.

*P ≤ 0.017.

P ≤ 0.006.